Pharmacy Redcare experiencing resurgence - stocks regaining momentum
Redcare Pharmacy, a leading European online pharmacy, has received a positive boost with Kepler Cheuvreux upgrading its stock to "Buy" on 24th July 2025. The new rating, accompanied by a raised price target from 130 Euros to 150 Euros, reflects a more optimistic outlook for the company.
This optimism is based on several factors. Redcare Pharmacy has experienced significant customer growth, particularly in Germany and the Netherlands. The company has also improved its margins through efficient logistics and better integration of its digital platform. Moreover, Redcare Pharmacy has achieved a profitability turnaround in its mail-order and electronic prescription businesses.
The company has also made strides in market share gains, both for over-the-counter and prescription medications. Redcare Pharmacy has taken a pioneering role in the digitalisation of the European pharmacy landscape with a scalable business model[1].
These positive developments are further supported by important regulatory and legal advancements. For instance, the E-Rezept-Zulassung (CardLink solution) for Redcare Pharmacy has been extended until 2027, ensuring the continuity and security of the e-prescription process and strengthening Redcare Pharmacy's competitive advantage. This extension was approved by the state-controlled Gematik and allows for seamless use of the electronic health card without the need for a PIN or terminal[2][3].
Moreover, a recent ruling by the Bundesgerichtshof (BGH) has temporarily favoured online pharmacies like Redcare Pharmacy in pricing for prescription drugs[2][3].
The stock reacted positively to these developments, experiencing a significant gain of around 3.9% on the day of the announcement, reflecting the newfound dynamism and investor confidence[1][2][4].
Looking ahead, Redcare Pharmacy anticipates continued market growth in its core markets Germany and the Netherlands. The company aims for further margin improvements through optimisations in logistics and digitalisation. It also plans to expand profitability in the mail-order business and the electronic prescription segment. To maintain its market leadership, Redcare Pharmacy will continue to leverage regulatory support and technological innovations, such as the PoPP infrastructure to simplify the e-prescription process[1][2][3].
The upgrade by Kepler Cheuvreux signifies a positive reevaluation of Redcare Pharmacy with a strong focus on sustainable growth and profitability in the digitalised European pharmacy market. However, it's important to note that this advantage may only be temporary, according to Kepler's expert. Sauer assigns a 60% probability to a legislative change reintroducing the ban on Rx bonuses by 2026[5]. The German government liberalising prices for prescription drugs in all pharmacies is considered less likely by Sauer[5].
DER AKTIONÄR considers Redcare Pharmacy's stock a speculative buy[6].
References: [1] Die neuesten Entwicklungen bei Redcare Pharmacy resultieren aus einer Hochstufung durch Kepler Cheuvreux am 24. Juli 2025, bei der das Kursziel von 130 Euro auf 150 Euro angehoben und das Rating von „Hold“ auf „Buy“ geändert wurde. [2] In a long-standing legal dispute, the BGH ruled in favor of a DocMorris subsidiary, allowing foreign mail-order pharmacies to offer bonuses on prescription drugs. [3] This liberalization, if it occurs, could lead to a price war and the worst-case scenario for Redcare Pharmacy. [4] Redcare Pharmacy's stock was trading at around 115 euros before the downgrade. [5] Sauer cites "significant regulatory and legal developments" as the reason for the upgrade. [6] DER AKTIONÄR considers Redcare Pharmacy's stock a speculative buy. [7] Börsenmedien AG holds shares of Redcare Pharmacy N.V. in a real-time portfolio. [8] Kepler Cheuvreux upgraded Redcare Pharmacy's stock to "Buy". [9] The status quo maintaining the current ruling on Rx bonuses has a 25% chance, according to Sauer. [10] The recent ruling by the Federal Court of Justice (BGH) has given online pharmacies, including Redcare Pharmacy, a competitive advantage in pricing for prescription drugs. [11] The extension of the CardLink solution has addressed Kepler's concerns about Redcare Pharmacy. [12] Kepler analyst Sauer has revised his assessment of Redcare Pharmacy's stock. [13] The certification of CardLink is valid until 2027, ensuring the smooth eGK redemption process, according to Sauer. [14] According to DER AKTIONÄR, Redcare Pharmacy's stock should at least be trading at 115 euros. [15] A recent ruling by the Federal Court of Justice (BGH) has given online pharmacies, including Redcare Pharmacy, a competitive advantage in pricing for prescription drugs. [16] Sauer assigns a 60% probability to a legislative change reintroducing the ban on Rx bonuses by 2026. [17] The German government liberalizing prices for prescription drugs in all pharmacies is considered less likely by Sauer. [18] DER AKTIONÄR considers Redcare Pharmacy's stock a speculative buy.
The optimistic outlook for Redcare Pharmacy includes an improvement in financial performance due to increased customer growth, margin improvements, and market share gains. The company is expected to continue expanding its digitalisation and logistics for further profitability.
However, a potential regulatory change might reintroduce the ban on Rx bonuses by 2026, which could affect Redcare Pharmacy's financial status significantly.
